A Single-Center Quasi-Experimental Study to Evaluate the Impact of Utilizing Rapid Diagnostic Technology to Detect Methicillin-Resistant
Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a relevant pathogen for patients with pneumonia in the presence of certain risk factors. Empiric broad-spectrum antimicrobial therapy, including anti-MRSA therapy, is frequently initiated in patients hospitalized with pneumonia. The low yield of respiratory cultures makes antimicrobial de-escalation difficult, potentially leading to extended durations of anti-MRSA therapy and increasing risk for significant drug-related adverse effects. A polymerase chain reaction (PCR) test that was previously utilized for nasal MRSA screening was internally validated to identify the presence of MRSA in respiratory specimens within 2 hours of sample collection. The primary objective of this study was to determine the effect of this respiratory PCR test on duration of anti-MRSA therapy in nonintensive care unit (ICU) patients hospitalized with pneumonia.
Methods. Implementation of the PCR test in non-ICU units occurred December 1, 2017. During the post-intervention (INT) period (December 1, 2017 -March 31, 2018 , PCR results were evaluated daily by antimicrobial stewardship and decentralized staff pharmacists for therapy de-escalation opportunities, with recommendations communicated to prescribers. The pre-INT group (December 1, 2016-March 31, 2017) consisted of non-ICU patients hospitalized with pneumonia who received anti-MRSA therapy for at least 48 hours, or who qualified for anti-MRSA therapy per institutional guidelines.
Results. A total of 169 patients were evaluated; 109 in the post-INT group and 60 in the pre-INT group. Anti-MRSA therapy was administered to 74 patients (68%) in the post-INT group, compared with 56 patients (93%) in the pre-INT group. The median duration of anti-MRSA therapy post-INT was 23.5 hours, which was significantly shorter than the pre-INT duration of 55.5 hours (P < 0.0001). The post-INT group also had significantly less vancomycin-induced nephrotoxicity (P < 0.0383) and a shorter time to targeted therapy (P < 0.0001). No difference in 30-day all-cause mortality was observed (P < 0.1338).
Conclusion. Utilization of a PCR test to detect MRSA in respiratory specimens decreased duration of anti-MRSA therapy in non-ICU patients hospitalized with pneumonia.
Disclosures. Results. A total of 3,621 RVPs were tested with 49 positive for MPP. In regard to age of patients, 27/49 (incidence 2.7%) positive for MPP were under 5 years old as compared with 22/49 (incidence 1%) between 5-18 years old. 75% of RVPs obtained were in patients under 5 years of age. Cough and fever were present for a mean of 8.3 and 7.6 days, respectively prior to RVP. Of the MPP positive patients, 21/49 patients (43%) were treated with scheduled although only 16 had a history of wheezing. Of the MPP positive patients, 38/48 patients had radiological findings of a pulmonary infiltrate (not perihilar) with 30/38 patients (79%) had bilateral infiltrates. Admission antimicrobial therapy was the following: 8 on no antibiotic, 21 on nonmacrolide, 11 macrolide and nonmacrolide, and 9 on macrolide therapy alone. Pediatric intensive care unit (PICU) admission occurred in 8 patients: 4 direct PICU admissions and 4 patients transferred from wards to PICU. All four PICU transfers had initially nonmacrolide therapy; 3 of 4 were under 5 years of age.
Conclusion. Over half of Pediatric MPP was diagnosed by rapid molecular diagnostics in patients under 5 years of age. Bilateral pulmonary infiltrates and new onset wheezing responsive to β agonists were commonly noted in patients who had MPP. A small subset of those younger patients required higher level of care after initial therapy with nonmacrolide therapy. While MPP has a lower incidence among younger children, the infection is not rare and can have a significant clinical impact. MPP should be considered in all patients, especially younger patients who are nonresponsive to treatment of community acquired pneumonia.
Disclosures. Background. From January 2012 PCV13 was introduced into immunization program in Argentina, 2 + 1 schedule for <2 years. The aims of this study were to describe epidemiological-clinical pattern of community-acquired bacteremic pneumonia (CABP) in the post-vaccination period and the risks factors of CABP occurrence, complications and lethality.
Methods. Cross-sectional study was performed in children with CABP diagnosis, hospitalized in Ricardo Gutierrez Children's Hospital from January 2012 to December 2017.
Results. A total of 135 CABP cases were included; 63% male; 31.1% <2 years; 75% of <5 years received PCV13; 30.4% had underlying diseases. The pathogens isolated were (n = 136): Streptococcus pneumoniae (Sp) 44.9% (all susceptible to Penicillin), Staphylococcus aureus (Sa) 37.5% (Methicillin-Resistant 90.2%), Haemophilus Conclusion. Our population-based surveillance system allows us to estimate the incidence of laboratory confirmed NPP. Given imperfect UAT sensitivity, this is an underestimate. A more sensitive and serotype-specific UAT could provide improved detection and understanding of NPP. Nonetheless, NPP surveillance allows us to better understand populations at risk for NPP and establish a baseline to evaluate impact of PCV13 on NPP incidence among adults. Background. Given the disparity in cost between inpatient and outpatient care, the IDSA/ATS community-acquired pneumonia (CAP) guidelines recommend use of site-of-care severity of illness indicators to identify CAP patients who may be candidates for outpatient treatment. Despite this level 1 recommendation, there are limited data on US hospital community-acquired bacterial pneumonia (CABP) admissions patterns stratified by Pneumonia Severity Index (PSI) score and presence of comorbidities. This study described hospitalization and length of stay (LOS) patterns among adult patients with CABP who received ceftriaxone (CTX) and a macrolide (M) at admission in the MedAssets database. The primary objective was to quantify the proportion of admissions and associated hospital LOS among "low-risk" patients (PSI score ≤ 90) where outpatient or short admission is advocated.
Methods. A retrospective study of patients hospitalized for CABP and in the MedAssets database during 2012-2015 was performed. Inclusion criteria: (1) age ≥ 18 years, (2) a primary diagnosis for CABP, (3) received CTX and a M on hospitalization Day 1 or 2, and (3) ≥1-year enrollment before the index date. For patients with multiple hospitalizations for CABP during the study period, only the first episode was considered. Distribution of hospital admissions was stratified by PSI categories and Charlson Comorbidity Index (CCI). Both PSI and CCI were derived from diagnosis codes. Hospital LOS and mortality rates were tabulated across resulting PSI-CCI categories.
Results. During the study period, 68,254 patients met inclusion criteria. Among hospitalized CABP patients, 35% had a PSI score ≤ 70 and 33% had a PSI score between 71-90. The mean LOS for patients with a PSI score ≤70 and 71-90 ranged between 5.2 and 6.6 days, depending on CCI score. Mortality was less than 0.5% for patients with PSI score ≤70 and 1.4% for patients with a 71-90 PSI score.
Conclusion. More than two-thirds of hospitalized CABP patients who received CTX and an M had a PSI score ≤ 90. On average, hospital LOS was 5-6 days for CABP patients with PSI ≤ 90. These findings reflect the critical need to identify outpatient treatments that can effectively reduce hospital admissions.
Disclosures.. T. Lodise, Paratek Pharmaceuticals: Consultant and Scientific Advisor, Consulting fee. K. LaPensee, Paratek Pharmaceuticals: Employee, Salary. October 5, 2018: 12:30 PM Background. Fluoroquinolones (FQs) are used commonly for patients with community acquired bacterial pneumonia (CABP). A recent FDA Drug Safety Communication strengthened labeling regarding tendinopathy/tendon rupture for FQs. The data prompting this change lacked a comparator group of patients using other antibiotics, like ceftriaxone/azithromycin (CTX-AZ) for similar indications. The objectives of this study were to compare the incidence of adverse tendon events (TE) between FQ and CTX-AZ among patients with CABP and determine if FQ treatment is independently associated with TE.
Comparative Evaluation of Adverse Tendon Events Between
Methods. A retrospective cohort study was performed among patients in the Upstate New York Veterans' Healthcare Administration. Inclusion criteria: (1) age ≥ 18 years, (2) diagnosis of CABP (ICD9 code with manual confirmation) from January 2014 to December 2015, (3) receipt of IV/oral FQ or CTX-AZ ≥ 1 day, and (4) treatment initiated as inpatient. Data were collected from pt's medical records. Occurrence of TE was defined using a natural word search algorithm of patients' clinical progress notes within 90 days of starting FQ or CTX-AZ therapy. Search terms were: tendinopathy, tendon pain, tendon rupture, tendinitis, and Achilles heel pain/tear/torn/rupture. Classification and regression tree (CART) was used to identify breakpoints in continuous variables associated with TE.
Results. There were 379 FQ and 274 CTX-AZ recipients. Mean ± standard deviation (SD) ages for FQ and CTX-AZ recipients were, 73.0 ± 12.7 vs. 72.8 ± 12.7 years, respectively. Mean (SD) APACHE-II was significantly higher for FQ than CTX-AZ recipients, 10.2 ± 5.1 vs. 8.5 ± 3.6, respectively (P < 0.001). Residence in the intensive care unit at start of therapy did not differ (FQ: 11.6% vs. CTX-AZ: 10.2%, P = 0.58). The incidence of TE did not differ between groups (FQ: 9/379 [2.4%] vs. CTX-AZ: 4/274 [1.5%], P = 0.57). In multivariate analyses (figure), treatment was not independently associated with TE (aOR: 1.78, 95% confidence interval: 0.51-6.21, P = 0.37) after adjustment for treatment duration, APACHE-II, age ≥52 years and BMI ≥27.5.
